These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 2042556)

  • 1. Significant FDA approvals in 1990.
    Rheinstein PH
    Am Fam Physician; 1991 Jun; 43(6):2257-8. PubMed ID: 2042556
    [No Abstract]   [Full Text] [Related]  

  • 2. Significant FDA approvals in 1988.
    Nightingale SL
    Am Fam Physician; 1989 Jun; 39(6):315-6. PubMed ID: 2729045
    [No Abstract]   [Full Text] [Related]  

  • 3. Significant FDA approvals in 1989.
    Nightingale SL
    Am Fam Physician; 1990 Jun; 41(6):1851-2. PubMed ID: 2349910
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA approvals. New drugs, new uses.
    Rodman MJ
    RN; 1991 Mar; 54(3):61-8. PubMed ID: 2003204
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA new drug approvals in 2009.
    Wynn RL
    Gen Dent; 2010; 58(4):280-4. PubMed ID: 20591770
    [No Abstract]   [Full Text] [Related]  

  • 6. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drugs and product approvals from 2000.
    Taylor SE; Gage TW
    Tex Dent J; 2001 Nov; 118(11):1070-81. PubMed ID: 11806330
    [No Abstract]   [Full Text] [Related]  

  • 8. The FDA new drug approval process.
    Gifford RW
    Conn Med; 1980 May; 44(5):309-11. PubMed ID: 7379526
    [No Abstract]   [Full Text] [Related]  

  • 9. Significant FDA approvals in 1994.
    Rheinstein PH
    Am Fam Physician; 1995 Mar; 51(4):888-90. PubMed ID: 7887364
    [No Abstract]   [Full Text] [Related]  

  • 10. Significant FDA approvals in 1996.
    Rheinstein PH
    Am Fam Physician; 1997 Jun; 55(8):2855-8. PubMed ID: 9191461
    [No Abstract]   [Full Text] [Related]  

  • 11. USAN and FDA.
    Am J Pharm Sci Support Public Health; 1966; 138(5):172-4. PubMed ID: 5976320
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA problems with medications in the marketplace: II.
    Archambault GF
    Hosp Formul; 1976 May; 11(5):272. PubMed ID: 1026690
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA still faces questions on drug safety.
    Med Health; 2005 Mar; 59(6 Spec no.):9-11. PubMed ID: 17063621
    [No Abstract]   [Full Text] [Related]  

  • 14. Should the FDA impose relative efficacy judgments?
    Stetler CJ
    Tex Med; 1972 Nov; 68(11):48-52. PubMed ID: 4634627
    [No Abstract]   [Full Text] [Related]  

  • 15. Significant FDA approvals in 2000.
    McGinnis TJ
    Am Fam Physician; 2001 May; 63(10):2061-4. PubMed ID: 11388719
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA to fast-track recombinant drugs.
    Am Pharm; 1981 Feb; NS21(2):19. PubMed ID: 7211687
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA pressure?
    Appleton BL
    Nature; 1990 Mar; 344(6262):99. PubMed ID: 2308647
    [No Abstract]   [Full Text] [Related]  

  • 18. New drugs: the AMA and FDA roles.
    Appel JZ
    J Ark Med Soc; 1966 Jul; 63(2):67-9. PubMed ID: 4223555
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA 'efficacy' rule: does it work?
    Lasagna L
    Mo Med; 1971 Sep; 68(9):712-4. PubMed ID: 5570164
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety-related drug labeling changes approved by FDA.
    White GG
    J Toxicol Clin Toxicol; 1998; 36(3):265-7. PubMed ID: 9678979
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.